期刊文献+

丹参酮对兔急性心梗再灌注损伤的心肌保护 被引量:6

Myocardium Protection of Tanshinone on Ischemia Reperfusion Injury of Rabbits with Acute Myocardial Infarction
原文传递
导出
摘要 目的探讨丹参酮在心肌梗死再灌注损伤中的干预作用,为临床治疗提供实验依据。方法将40只,♂,新西兰大白兔按成组设计应用随机列表法分成4组,每组10只:葡萄糖再灌注组、丹参酮再灌注治疗组、丹参酮冠脉结扎前治疗组和假手术组。建立再灌注模型后经耳缘静脉给药。分别于结扎前5 min、结扎后1 h、再灌注后2 h时,取血清检测肌酸激酶(CK)、肌酸激酶的同功酶(CK-MB)、肌钙蛋白Ⅰ(Tn-Ⅰ)。并于再灌注后2 h,以1%的四氮唑红溶液制作心肌切片,以AutoCAD 2002图形设计软件计算坏死心肌范围。结果①丹参酮再灌注组与葡萄糖再灌注组、丹参酮结扎前治疗组与葡萄糖再灌注组在再灌注后2 h的CK、CK-MB、Tn-Ⅰ有统计学差异(P<0.05);丹参酮再灌注组与丹参酮结扎前治疗组在再灌注后2 h的CK、CK-MB无统计学差异(P>0.05)、Tn-Ⅰ有统计学差异(P<0.05)。②丹参酮再灌注组与葡萄糖再灌注组、丹参酮结扎前治疗组与葡萄糖再灌注组心肌梗死范围比较有统计学差异(P<0.05)。丹参酮再灌注组与丹参酮结扎前治疗组无统计学差异(P>0.05)。结论静脉注射丹参酮可以降低兔急性心肌梗死再灌注后CK、CK-MB、Tn-Ⅰ,并减少兔急性心肌梗死面积。 OBJECTIVE To explore the effect of tanshinone on ischemia reperfusion injury of rabbits after acute myocardial infarction, and to supply the experimental proof for the clinic. METHODS Divide 40 male rabbits into 4 groups, 10 per group: glucose reperfusion group, tanshinone reperfusion group, tanshinone pre-blocking treatment group and sham-operation group. Reperfusion injury model was established and the drug was administrated intravenously. Blood was collected to test the CK, CK-MB, Tn- I at the time of 5 min pre-blocking, 1 h post-blocking and 2 h post reperfusion. 1% Triphenyltetrazolium chloride was used to produce myocardial incision. AutoCAD 2002 software was applied to calculate the area of myocardial infarction. RESULTS (~Tanshinone reperfusion group and glucose reperfusion group had significant differences in CK, CK-MB, Tn-I after 2 h reperfusion(P〈0.05). Tanshinone pre-blocking treatment group and glucose reperfusion group had significant differences in CK, CK-MB, Tn- I after 2 h reperfusion(P〈0.05). Tanshinone reperfusion group and tanshinone pre-blocking treatment group had no significant differences in CK, CK-MB after 2 h reperfusion(P〉0.05), and had significant differences in Tn- I after 2 h reperfusion(P〈0.05). (~)The area of myocardial infarction between tanshinone reperfusion group and glucose reperfusion group, tanshinone pre-blocking treatment group and glucose reperfusion group had significant differences(P〈0.05). The area of myocardial infarction between tanshinone reperfusion group and tanshinone pre-blocking treatment group had no significant differences(P〉0.05). CONCLUSION Tanshinone can lower CK, CK-MB, Tn- I of rabbits with acute myocardial infarction, and can decrease the area of myocardial infarction.
出处 《中国现代应用药学》 CAS CSCD 2013年第10期1062-1066,共5页 Chinese Journal of Modern Applied Pharmacy
基金 浙江省中医药科技计划项目(2009CA038)
关键词 丹参酮 心肌缺血再灌注损伤 心肌保护 tanshinone ischemia reperfusion injury myocardium protection
  • 相关文献

参考文献3

二级参考文献25

  • 1杨解人,熊莺,丁伯平,陈国祥.丹参葡萄糖注射液对犬冠脉结扎急性心肌缺血模型的血气分析[J].中国实验方剂学杂志,2004,10(6):45-47. 被引量:7
  • 2宋晓亮,高广猷,叶丽虹.山麦冬总电甙对实验性心肌缺血的影响[J].中国药理学通报,1996,21(4):329-332. 被引量:43
  • 3汪丽娟,宋伟,汤宁,吕杰胜,黄幼田,邬文海,王柏生.等容血液稀释和丹参对缺血再灌注心肌的保护作用[J].微循环技术杂志(临床与实验),1996,4(2):78-80. 被引量:4
  • 4程能能 孙瑞元.新药数据的统计处理及NDST程序[J].皖南医学院学报,1994,13:28-30.
  • 5.
  • 6TAKESHITA S, PU LQ, STEIN CA, et al. Intramuscular administration of VEGF induces does-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia[J]. Circulation, 1994, 90(partⅡ): 228-234.
  • 7MAKINEN K, MANNINEN H, HEDMAN M, et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized,placebo- controlled, double-blinded phase Ⅱ study[J]. Mol Ther,2002, 6(1): 127-133.
  • 8FREEDMAN SB, ISNER JM. Therapeutic angiogenesis for coronary artery disease[J]. Ann Intern Med, 2002, 136(1): 54-71.
  • 9MERKLE CJ, MONTGOMERY DW. Gene therapy with vascular endothelial growth factor reduces angina[J]. J Cardiovasc Nurs,2003, 18(1): 38-43.
  • 10JI X, TAN BK, ZHU YC, et al. Comparison of cardioprotective effects using ramipril and DanShen for the treatment of acute myocardial infarction in rats [J]. Life Sci, 2003, 73 (11):1413-1416. Chinese.

共引文献29

同被引文献43

  • 1马平勃,朱全红,黄中伟.绞股蓝泡服对实验性高脂血症及血液流变学的影响[J].中国现代应用药学,2005,22(6):454-455. 被引量:43
  • 2SENA C M, PEREIRA A M, SEI(A R. Endothelial dysfunc- tion-a major mediator of diabetic vascular disease [J]. Biochim Biophys Acta, 2013, 1832(12): 2216-2231.
  • 3REINHART W H. Platelets in vascular disease [J]. Clin Hemorheol Microcirc, 2013, 53(1/2): 71-79.
  • 4VELCHEVA I, DAMIANOV P, ANTONOVA N,et al. Hemorheology and vascular reactivity in patients with diabetes mellitus type 2 [J]. Clin Hemorheol Microcirc, 2011, 49(1-4): 505-511.
  • 5RICHARDS R S, NWOSE E U. Blood viscosity at different stages of diabetes pathogenesis [J]. Br J Biomed Sci, 2010, 67(2): 67-70.
  • 6TAMARIZ L J, YOUNG J H, PANKOW J S, et al. Blood viscosity and hematocrit as risk factors for type 2 diabetes mellitus: the atherosclerosis risk in communities (ARIC) study [J]. Am J Epidemiol, 2008, 168(10): 1153-1160.
  • 7CERBONE A M, MACARONE-PALMIERI N, SALDALA- MACCHIA G, et al. Diabetes, vascular complications and antiplatelet therapy: open problems [J]. Aeta Diabetol, 2009, 46(4): 253-261.
  • 8MONTEZANO A C, TOUYZ R M. Reactive oxygen species and endothelial function-role of nitric oxide synthase uncoupling and Nox family nicotinamide adenine dinucleotide phosphate oxidases [J]. Basic Clin Pharmacol Toxicol, 2012, 110(1): 87-94.
  • 9周亚滨,吴凤兰,杨莺,刘淑娟,周兰.益气养阴活血化瘀方对实验性病毒性扩张型心肌病小鼠心肌穿孔素mRNA表达的影响[J].辽宁中医杂志,2008,35(6):830-832. 被引量:4
  • 10王照华,郑智,梁黔生,孙丽萍,张存泰.丹参酮对肥厚心肌中电生理异常的干预[J].中华急诊医学杂志,2008,17(10):1039-1044. 被引量:9

引证文献6

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部